Merck Announces Presentation of Phase III Investigational Studies Evaluating DULERA(r) (mometasone furoate and formoterol fumarate dihydrate) Inhalation Aerosol in Chronic Obstructive Pulmonary Disease (COPD).

The article announces the presentation of Merck & Co. Inc.'s Phase III Investigational Studies that evaluates the safety and efficacy of DULERA(r) (mometasone furoate and formoterol fumarate dihydrate) in patients with severe chronic obstructive pulmonary disease (COPD). The studies reveal the efficacy of DULERA in improving the function of lungs from the baseline as compared to mometasone furoate. It also shows the adverse events of the treatment from mild to moderate.